Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 08:05 pm
Share
Glaukos Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 78.05 million compared to USD 71.27 million a year ago. Net loss was USD 30.44 million compared to USD 27.58 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.58 a year ago. Diluted loss per share from continuing operations was USD 0.63 compared to USD 0.58 a year ago.
For the nine months, sales was USD 232.35 million compared to USD 211.64 million a year ago. Net loss was USD 97.88 million compared to USD 67.74 million a year ago. Basic loss per share from continuing operations was USD 2.03 compared to USD 1.43 a year ago. Diluted loss per share from continuing operations was USD 2.03 compared to USD 1.43 a year ago.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.